tooluniverse-drug-repurposing

Identify drug repurposing candidates by querying ToolUniverse databases for targets, safety, and literature evidence.

Updated Mar 13, 2026
One-click install
npx skills add https://github.com/matt-grain/pharma-catalyst --skill tooluniverse-drug-repurposing-matt-grain
Or copy as Structured Prompt for Agent▼
Please help me install this Agent Skill.
Skill: tooluniverse-drug-repurposing
Source: https://github.com/matt-grain/pharma-catalyst/tree/main/.claude/skills/tooluniverse-drug-repurposing
Command: npx skills add https://github.com/matt-grain/pharma-catalyst --skill tooluniverse-drug-repurposing-matt-grain

SYSTEM DOCUMENTATION & REQUIREMENTS

💡 This Skill requires tooluniverse.

What problem does it solve? Finding new therapeutic uses for existing drugs requires manually searching dozens of disconnected databases (DrugBank, OpenTargets, ChEMBL, FAERS, PubMed) and synthesizing target, safety, and literature evidence. This Skill automates that multi-database workflow so researchers can systematically rank repurposing candidates instead of spending weeks on manual literature and database review. ## Core Features & Use Cases - Three Repurposing Strategies: Target-based (disease targets to drugs), compound-based (approved drugs to new indications), and disease-driven (disease to targets to existing drugs), plus mechanism, network, phenotype, and structure-based variants. - Integrated Safety Assessment: Pulls FDA warnings, FAERS adverse event counts, death-related reports, and drug-drug interactions, plus ADMET/toxicity predictions via ADMET-AI. - Composite Scoring & Ranking: Scores candidates 0-100 across target association, safety profile, literature evidence, and drug properties, with a ready-made report template. - Use Case: Given a disease like Alzheimer's, retrieve its top OpenTargets-associated genes, find approved drugs hitting those targets via DGIdb and DrugBank, filter out drugs already indicated for the disease, then rank survivors by FAERS safety data and PubMed/clinical trial evidence. ## Quick Start Ask the assistant to find drug repurposing candidates for a specific disease using ToolUniverse, and it will retrieve disease targets, matching approved drugs, safety profiles, and literature evidence, then return a scored and ranked candidate list.

Frequently Asked Questions about tooluniverse-drug-repurposing

High-intent search queries and answers about installing and using this skill.

FAQPage Schema
How do I find drug repurposing candidates for a disease?▼

Look up the disease in OpenTargets to get its EFO ID, retrieve associated targets, then query DGIdb and DrugBank for drugs interacting with those targets. Filter to approved drugs not already indicated for the disease, then score candidates on safety and literature evidence.

What databases does ToolUniverse search for drug repurposing?▼

The workflow covers DrugBank, OpenTargets, DGIdb, ChEMBL, PubChem, UniProt, FDA labels, FAERS adverse events, PubMed, Europe PMC, and ClinicalTrials.gov. Cross-database validation of drug-target interactions is recommended before ranking candidates.

How are drug repurposing candidates scored and ranked?▼

Candidates receive a composite 0-100 score: up to 40 points for target association strength, 30 for safety profile and approval status, 20 for literature and clinical trial evidence, and 10 for drug-like properties such as bioavailability.

Why does FAERS return empty results for a drug name?▼

FAERS queries require uppercase drug names such as ASPIRIN rather than aspirin. If results are still empty, try brand names, check spelling, or verify the drug has sufficient US adverse event reports in OpenFDA.

Can I use structure similarity to find repurposing candidates?▼

Yes. Retrieve the compound's PubChem CID and SMILES, then run a similarity search at a threshold like 85 percent. Check which similar compounds are approved drugs and evaluate them against the target disease with literature searches.

What are the limitations of computational drug repurposing screening?▼

Results depend on database coverage, so non-US-approved drugs may lack FDA safety data and poorly studied targets may return no drugs. All ranked candidates still require experimental validation and clinical trials before any therapeutic use.